Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.

  • 1.

    KhoranaAAFrancisCWCulakovaE. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol2006;24:484490.

  • 2.

    SallahSWanJYNguyenNP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost2002;87:575579.

    • Search Google Scholar
    • Export Citation
  • 3.

    KhoranaAADalalMLinJConnollyGC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer2013;119:648655.

    • Search Google Scholar
    • Export Citation
  • 4.

    HeitJAO’FallonWMPettersonTM. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med2002;162:12451248.

    • Search Google Scholar
    • Export Citation
  • 5.

    MonrealMFernandez-LlamazaresJPerandreuJ. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost1997;78:13161318.

    • Search Google Scholar
    • Export Citation
  • 6.

    BickRL. Cancer-associated thrombosis: focus on extended therapy with dalteparin. J Support Oncol2006;4:115120.

  • 7.

    LopezJAKearonCLeeAY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program2004:439456.

  • 8.

    PrandoniPPiccioliAGirolamiA. Cancer and venous thromboembolism: an overview. Haematologica1999;84:437445.

  • 9.

    OttenHMMathijssenJten CateH. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med2004;164:190194.

    • Search Google Scholar
    • Export Citation
  • 10.

    ChewHKWunTHarveyD. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med2006;166:458464.

    • Search Google Scholar
    • Export Citation
  • 11.

    ChewHKWunTHarveyDJ. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol2007;25:7076.

    • Search Google Scholar
    • Export Citation
  • 12.

    KudererNMFrancisCWCulakovaE. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 9521.

    • Search Google Scholar
    • Export Citation
  • 13.

    MartinoMAWilliamsonESiegfriedS. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol2005;98:289293.

    • Search Google Scholar
    • Export Citation
  • 14.

    SorensenHTMellemkjaerLOlsenJHBaronJA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med2000;343:18461850.

  • 15.

    AgnelliGBolisGCapussottiL. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg2006;243:8995.

    • Search Google Scholar
    • Export Citation
  • 16.

    CohenATAlikhanRArcelusJI. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost2005;94:750759.

    • Search Google Scholar
    • Export Citation
  • 17.

    KhoranaAAConnollyGC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol2009;27:48394847.

  • 18.

    ConnollyGCKhoranaAA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res2010;125(Suppl 2):17.

    • Search Google Scholar
    • Export Citation
  • 19.

    Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations—United States, 2007-2009. MMWR Morb Mortal Wkly Rep2012;61:401404.

    • Search Google Scholar
    • Export Citation
  • 20.

    AgenoWSquizzatoAGarciaDImbertiD. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost2006;32:651658.

  • 21.

    HicksLKCheungMCDingK. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer2009;115:55165525.

    • Search Google Scholar
    • Export Citation
  • 22.

    KhoranaAAKudererNMCulakovaE. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood2008;111:49024907.

    • Search Google Scholar
    • Export Citation
  • 23.

    KhoranaAAFrancisCWCulakovaELymanGH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer2005;104:28222829.

    • Search Google Scholar
    • Export Citation
  • 24.

    MandalàMBarniSPrinsM. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol2010;21:871876.

    • Search Google Scholar
    • Export Citation
  • 25.

    DarzeESLatadoALGuimaraesAG. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest2005;128:25762580.

    • Search Google Scholar
    • Export Citation
  • 26.

    KrogerKWeilandDOseC. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol2006;17:297303.

  • 27.

    PrandoniPLensingAWPrinsMH. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med2002;137:955960.

    • Search Google Scholar
    • Export Citation
  • 28.

    PrandoniPLensingAWPiccioliA. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002;100:34843488.

    • Search Google Scholar
    • Export Citation
  • 29.

    RogersMALevineDABlumbergN. Triggers of hospitalization for venous thromboembolism. Circulation2012;125:20922099.

  • 30.

    SchmidtMHorvath-PuhoEThomsenRW. Acute infections and venous thromboembolism. J Intern Med2012;271:608618.

  • 31.

    BlomJWDoggenCJOsantoSRosendaalFR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA2005;293:715722.

  • 32.

    HeitJASilversteinMDMohrDN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med2000;160:809815.

    • Search Google Scholar
    • Export Citation
  • 33.

    OgrenMBergqvistDWahlanderK. Trousseau’s syndrome: what is the evidence? A population-based autopsy study. Thromb Haemost2006;95:541545.

    • Search Google Scholar
    • Export Citation
  • 34.

    HallIEAndersenMSKrumholzHMGrossCP. Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol2009;2009:182521182521.

    • Search Google Scholar
    • Export Citation
  • 35.

    SandhuRPanCXWunT. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer2010;116:25962603.

    • Search Google Scholar
    • Export Citation
  • 36.

    LevitanNDowlatiARemickSC. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore)1999;78:285291.

    • Search Google Scholar
    • Export Citation
  • 37.

    GerberDEGrossmanSAStreiffMB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol2006;24:13101318.

    • Search Google Scholar
    • Export Citation
  • 38.

    LeeAYLevineMN. Venous thromboembolism and cancer: risks and outcomes. Circulation2003;107:I1721.

  • 39.

    MarrasLCGeertsWHPerryJR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer2000;89:640646.

    • Search Google Scholar
    • Export Citation
  • 40.

    ConnollyGCDalalMLinJKhoranaAA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer2012;78:253258.

    • Search Google Scholar
    • Export Citation
  • 41.

    FalangaAMarchettiM. Venous thromboembolism in the hematologic malignancies. J Clin Oncol2009;27:48484857.

  • 42.

    PalumboARajkumarSVDimopoulosMA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia2008;22:414423.

    • Search Google Scholar
    • Export Citation
  • 43.

    OttingerHBelkaCKozoleG. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin’s lymphoma: incidence, causes and prognostic relevance. Eur J Haematol1995;54:186194.

    • Search Google Scholar
    • Export Citation
  • 44.

    AndtbackaRHBabieraGSingletarySE. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg2006;243:96101.

    • Search Google Scholar
    • Export Citation
  • 45.

    HaddadTCGreenoEW. Chemotherapy-induced thrombosis. Thromb Res2006;118:555568.

  • 46.

    AyCDunklerDMarosiC. Prediction of venous thromboembolism in cancer patients. Blood2010;116:53775382.

  • 47.

    CummingsSREckertSKruegerKA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA1999;281:21892197.

    • Search Google Scholar
    • Export Citation
  • 48.

    DecensiAMaisonneuvePRotmenszN. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation2005;111:650656.

    • Search Google Scholar
    • Export Citation
  • 49.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst2005;97:16521662.

    • Search Google Scholar
    • Export Citation
  • 50.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998;90:13711388.

    • Search Google Scholar
    • Export Citation
  • 51.

    VogelVGCostantinoJPWickerhamDL. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila)2010;3:696706.

    • Search Google Scholar
    • Export Citation
  • 52.

    AndersonGLLimacherMAssafAR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA2004;291:17011712.

    • Search Google Scholar
    • Export Citation
  • 53.

    RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA2002;288:321333.

    • Search Google Scholar
    • Export Citation
  • 54.

    Blanco-MolinaATrujillo-SantosJTiradoR. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost2009;101:478482.

    • Search Google Scholar
    • Export Citation
  • 55.

    GomesMPDeitcherSR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med2004;164:19651976.

    • Search Google Scholar
    • Export Citation
  • 56.

    LidegaardONielsenLHSkovlundCW. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ2011;343:d6423.

    • Search Google Scholar
    • Export Citation
  • 57.

    ManzoliLDe VitoCMarzuilloC. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf2012;35:191205.

    • Search Google Scholar
    • Export Citation
  • 58.

    JickSSHernandezRK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ2011;342:d2151.

    • Search Google Scholar
    • Export Citation
  • 59.

    ParkinLSharplesKHernandezRKJickSS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ2011;342:d2139.

    • Search Google Scholar
    • Export Citation
  • 60.

    LeafANPropertKCorcoranC. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol2003;20:137146.

    • Search Google Scholar
    • Export Citation
  • 61.

    BennettCLAngelottaCYarnoldPR. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA2006;296:25582560.

    • Search Google Scholar
    • Export Citation
  • 62.

    El AccaouiRNShamseddeenWATaherAT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost2007;97:10311036.

  • 63.

    HusseinMA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost2006;95:924930.

    • Search Google Scholar
    • Export Citation
  • 64.

    KnightRDeLapRJZeldisJB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med2006;354:20792080.

  • 65.

    WeberDMChenCNiesvizkyR. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med2007;357:21332142.

    • Search Google Scholar
    • Export Citation
  • 66.

    ZangariMSiegelEBarlogieB. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood2002;100:11681171.

    • Search Google Scholar
    • Export Citation
  • 67.

    BennettCLSilverSMDjulbegovicB. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA2008;299:914924.

    • Search Google Scholar
    • Export Citation
  • 68.

    BaarslagHJKoopmanMMHuttenBA. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med2004;15:503507.

    • Search Google Scholar
    • Export Citation
  • 69.

    PrandoniPPolistenaPBernardiE. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med1997;157:5762.

    • Search Google Scholar
    • Export Citation
  • 70.

    VersoMAgnelliG. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol2003;21:36653675.

    • Search Google Scholar
    • Export Citation
  • 71.

    LeeAYLevineMNButlerG. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol2006;24:14041408.

    • Search Google Scholar
    • Export Citation
  • 72.

    JoffeHVGoldhaberSZ. Upper-extremity deep vein thrombosis. Circulation2002;106:18741880.

  • 73.

    LinenbergerML. Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw2006;4:889901.

  • 74.

    van RoodenCJSchippersEFBargeRM. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol2005;23:26552660.

    • Search Google Scholar
    • Export Citation
  • 75.

    GarciaDABaglinTPWeitzJISamamaMM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141:e24S43S.

    • Search Google Scholar
    • Export Citation
  • 76.

    KahnSRLimWDunnAS. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141:e195S226S.

    • Search Google Scholar
    • Export Citation
  • 77.

    KearonCAklEAComerotaAJ. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141:e419S494S.

    • Search Google Scholar
    • Export Citation
  • 78.

    WellsPSAndersonDRRodgerMA. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med2005;165:733738.

    • Search Google Scholar
    • Export Citation
  • 79.

    sanofi-aventis US LLC. Prescribing information: Lovenox (enoxaparin sodium injection). 2009. Available at: http://products.sanofi-aventis.us/lovenox/lovenox.html. Accessed February 1 2011.

    • Search Google Scholar
    • Export Citation
  • 80.

    LEO Pharmaceutical Products. Prescribing information: Innohep (tinzaparin sodium injection) for subcutaneous (SC) use only. 2008. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020484s011lbl.pdf. Accessed February 18 2011.

    • Search Google Scholar
    • Export Citation
  • 81.

    Eisai Inc; Pfizer Inc.Prescribing information: FRAGMIN (dalteparin sodium injection) for subcutaneous use only. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020287s050lbl.pdf. Accessed March 11 2011.

    • Search Google Scholar
    • Export Citation
  • 82.

    CheerSMDunnCJFosterR. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs2004;64:14791502.

    • Search Google Scholar
    • Export Citation
  • 83.

    LeeAYLevineMNBakerRI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med2003;349:146153.

    • Search Google Scholar
    • Export Citation
  • 84.

    NeelyJLCarlsonSSLenhartSE. Tinzaparin sodium: a low-molecular-weight heparin. Am J Health Syst Pharm2002;59:14261436.

  • 85.

    NutescuEAShapiroNLFeinsteinHRiversCW. Tinzaparin: considerations for use in clinical practice. Ann Pharmacother2003;37:18311840.

  • 86.

    PlanesASamamaMMLensingAW. Prevention of deep vein thrombosis after hip replacement—comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost1999;81:2225.

    • Search Google Scholar
    • Export Citation
  • 87.

    MandalàMFalangaARoilaF. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol2008;19(Suppl 2):126127.

    • Search Google Scholar
    • Export Citation
  • 88.

    CookLMKahnSRGoodwinJKovacsMJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost2007;5:937941.

    • Search Google Scholar
    • Export Citation
  • 89.

    HirshJBauerKADonatiMB. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest2008;133:141S159S.

    • Search Google Scholar
    • Export Citation
  • 90.

    MichotaFMerliG. Anticoagulation in special patient populations: are special dosing considerations required?Cleve Clin J Med2005;72(Suppl 1):S3742.

    • Search Google Scholar
    • Export Citation
  • 91.

    SanderinkGJGuimartCGOzouxML. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res2002;105:225231.

    • Search Google Scholar
    • Export Citation
  • 92.

    LimWDentaliFEikelboomJWCrowtherMA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med2006;144:673684.

    • Search Google Scholar
    • Export Citation
  • 93.

    HulotJSMontalescotGLechatP. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther2005;77:542552.

    • Search Google Scholar
    • Export Citation
  • 94.

    KruseMWLeeJJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J2004;148:582589.

    • Search Google Scholar
    • Export Citation
  • 95.

    ShprecherARCheng-LaiAMadsenEM. Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy2005;25:817822.

    • Search Google Scholar
    • Export Citation
  • 96.

    DouketisJCookDMeadeM. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med2008;168:18051812.

    • Search Google Scholar
    • Export Citation
  • 97.

    MaheIAghassarianMDrouetL. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost2007;97:581586.

    • Search Google Scholar
    • Export Citation
  • 98.

    PautasEGouinIBellotO. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf2002;25:725733.

    • Search Google Scholar
    • Export Citation
  • 99.

    SiguretVPautasEFevrierM. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost2000;84:800804.

    • Search Google Scholar
    • Export Citation
  • 100.

    LeizoroviczA. Tinzaparin Compared to Unfractionated Heparin for Initial Treatment of Deep Vein Thrombosis in Very Elderly Patients with Renal Insufficiency-the IRIS Trial [abstract]. Blood2008;112:Abstract 434.

    • Search Google Scholar
    • Export Citation
  • 101.

    KucherNLeizoroviczAVaitkusPT. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med2005;165:341345.

    • Search Google Scholar
    • Export Citation
  • 102.

    GlaxoSmithKline. Prescribing information: ARIXTRA (fondaparinux sodium) solution for subcutaneous injection. 2011. Available at: http://us.gsk.com/products/assets/us_arixtra.pdf. Accessed May 11 2012.

    • Search Google Scholar
    • Export Citation
  • 103.

    PrandoniP. How I treat venous thromboembolism in patients with cancer. Blood2005;106:40274033.

  • 104.

    SaviPChongBHGreinacherA. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood2005;105:139144.

    • Search Google Scholar
    • Export Citation
  • 105.

    WarkentinTEGreinacherAKosterALincoffAM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest2008;133:340S380S.

    • Search Google Scholar
    • Export Citation
  • 106.

    CohenATDavidsonBLGallusAS. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ2006;332:325329.

    • Search Google Scholar
    • Export Citation
  • 107.

    Janssen Pharmaceuticals Inc.Prescribing Information: XARELTO (rivaroxaban) tablets. 2011. Available at: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100. Accessed May 11 2012.

    • Search Google Scholar
    • Export Citation
  • 108.

    CohenATSpiroTEBullerHR. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med2013;368:513523.

  • 109.

    BullerHRPrinsMHLensinAW. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med2012;366:12871297.

  • 110.

    Bristol-Myers Squibb Company. Prescribing Information: ELIQUIS (apixaban) tablets for oral use. 2012. Available at: http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed March 11 2013.

    • Search Google Scholar
    • Export Citation
  • 111.

    GoldhaberSZLeizoroviczAKakkarAK. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med2011;365:21672177.

    • Search Google Scholar
    • Export Citation
  • 112.

    AgnelliGBullerHRCohenA. Apixaban for extended treatment of venous thromboembolism. N Engl J Med2013;368:699708.

  • 113.

    AgnelliGBullerHRCohenA. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med2013;369:513523.

  • 114.

    HirshJAnandSSHalperinJLFusterV. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol2001;21:10941096.

    • Search Google Scholar
    • Export Citation
  • 115.

    ClagettGPReischJS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg1988;208:227240.

    • Search Google Scholar
    • Export Citation
  • 116.

    GeertsWHBergqvistDPineoGF. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest2008;133:453.

    • Search Google Scholar
    • Export Citation
  • 117.

    KingCSHolleyABJacksonJL. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest2007;131:507516.

    • Search Google Scholar
    • Export Citation
  • 118.

    KearonCGinsbergJSJulianJA. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA2006;296:935942.

    • Search Google Scholar
    • Export Citation
  • 119.

    Hospira Inc.Prescribing information: Heparin sodium injection USP. 2008. Available at: http://www.hospira.com/Files/heparin_sodium_injection.pdf. Accessed February 1 2011.

    • Search Google Scholar
    • Export Citation
  • 120.

    Bristol-Myers Squibb. Prescribing information: COUMADIN® TABLETS (Warfarin Sodium Tablets USP); COUMADIN® FOR INJECTION (Warfarin Sodium for Injection USP). 2010. Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed February 1 2011.

    • Search Google Scholar
    • Export Citation
  • 121.

    GlynnRJRidkerPMGoldhaberSZBuringJE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med2007;147:525533.

    • Search Google Scholar
    • Export Citation
  • 122.

    BecattiniCAgnelliGPoggioR. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study [abstract]. Blood2011;118:Abstract 543.

    • Search Google Scholar
    • Export Citation
  • 123.

    BecattiniCAgnelliGSchenoneA. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med2012;366:19591967.

  • 124.

    BrightonTAEikelboomJWMannK. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med2012;367:19791987.

  • 125.

    DennisMSandercockPAReidJ. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet2009;373:19581965.

    • Search Google Scholar
    • Export Citation
  • 126.

    Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation2005;112:416422.

    • Search Google Scholar
    • Export Citation
  • 127.

    BrenderE. Use of emboli-blocking filters increases, but rigorous data are lacking. JAMA2006;295:989990.

  • 128.

    SteinPDKayaliFOlsonRE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med2004;164:15411545.

  • 129.

    StreiffMB. Vena caval filters: a comprehensive review. Blood2000;95:36693677.

  • 130.

    StreiffMB. Vena caval filters: a review for intensive care specialists. J Intensive Care Med2003;18:5979.

  • 131.

    DecoususHLeizoroviczAParentF. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med1998;338:409415.

    • Search Google Scholar
    • Export Citation
  • 132.

    EltingLSEscalanteCPCooksleyC. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med2004;164:16531661.

    • Search Google Scholar
    • Export Citation
  • 133.

    GetzenTMRectenwaldJE. Inferior vena cava filters in the cancer patient: current use and indications. J Natl Compr Canc Netw2006;4:881888.

    • Search Google Scholar
    • Export Citation
  • 134.

    MillwardSFGrassiCJKinneyTB. Reporting standards for inferior vena caval filter placement and patient follow-up: supplement for temporary and retrievable/optional filters. J Vasc Interv Radiol2005;16:441443.

    • Search Google Scholar
    • Export Citation
  • 135.

    KimHSYoungMJNarayanAK. A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. J Vasc Interv Radiol2008;19:393399.

    • Search Google Scholar
    • Export Citation
  • 136.

    NicholsonWNicholsonWJTolericoP. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med2010;170:18271831.

    • Search Google Scholar
    • Export Citation
  • 137.

    CerveraRKhamashtaMAShoenfeldY. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2009;68:14281432.

    • Search Google Scholar
    • Export Citation
  • 138.

    LimWCrowtherMAEikelboomJW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA2006;295:10501057.

  • 139.

    LimW. Antiphospholipid antibody syndrome. Hematology Am Soc Hematol Educ Program2009:233239.

  • 140.

    FrancisCW. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol2009;27:48744880.

  • 141.

    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg1997;84:10991103.

    • Search Google Scholar
    • Export Citation
  • 142.

    MismettiPLaporteSDarmonJY. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg2001;88:913930.

    • Search Google Scholar
    • Export Citation
  • 143.

    DeBernardoRLPerkinsRBLittellRD. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. Obstet Gynecol2005;105:10061011.

    • Search Google Scholar
    • Export Citation
  • 144.

    AklEATerrenatoIBarbaM. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med2008;168:12611269.

    • Search Google Scholar
    • Export Citation
  • 145.

    CoubanSGoodyearMBurnellM. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol2005;23:40634069.

    • Search Google Scholar
    • Export Citation
  • 146.

    KarthausMKretzschmarAKroningH. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol2006;17:289296.

    • Search Google Scholar
    • Export Citation
  • 147.

    VersoMAgnelliGBertoglioS. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol2005;23:40574062.

    • Search Google Scholar
    • Export Citation
  • 148.

    YoungAMBillinghamLJBegumG. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet2009;373:567574.

    • Search Google Scholar
    • Export Citation
  • 149.

    KhoranaAADalalMTangiralaKMiaoR. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among U.S. cancer patients [abstract]. Blood2011;118:Abstract 674.

    • Search Google Scholar
    • Export Citation
  • 150.

    MartinoMABorgesEWilliamsonE. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol2006;107:666671.

    • Search Google Scholar
    • Export Citation
  • 151.

    BergqvistDAgnelliGCohenAT. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med2002;346:975980.

    • Search Google Scholar
    • Export Citation
  • 152.

    RasmussenMSJorgensenLNWille-JorgensenP. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost2006;4:23842390.

    • Search Google Scholar
    • Export Citation
  • 153.

    RanaPLevineMN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol2009;27:48854888.

  • 154.

    ZangariMFinkLMEliceF. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol2009;27:48654873.

  • 155.

    GayFHaymanSRLacyMQ. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood2010;115:13431350.

    • Search Google Scholar
    • Export Citation
  • 156.

    RajkumarSVJacobusSCallanderNS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol2010;11:2937.

    • Search Google Scholar
    • Export Citation
  • 157.

    Celgene Corporation. Prescribing information: REVLIMID (lenalidomide) capsules. 2010. Available at: http://www.revlimid.com/pdf/REVLIMID_PI.pdf. Accessed February 1 2011.

    • Search Google Scholar
    • Export Citation
  • 158.

    Celgene Corporation. Prescribing information: THALOMID® (thalidomide) Capsules 50 mg 100 mg 150 mg & 200 mg. 2010. Available at: http://www.thalomid.com/pdf/Thalomid%20PI%2072991-10.pdf. Accessed February 1 2011.

    • Search Google Scholar
    • Export Citation
  • 159.

    PalumboACavoMBringhenS. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol2011;29:986993.

    • Search Google Scholar
    • Export Citation
  • 160.

    LaroccaACavalloFBringhenS. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood2012;119:933939; quiz 1093.

    • Search Google Scholar
    • Export Citation
  • 161.

    KearneyJCRossiSGlinertKHenryDH. Venous thromboembolism (VTE) and survival in a cancer chemotherapy outpatient clinic: a retrospective chart review validation of a VTE predictive model [abstract]. Blood2009;114:Abstract 2503.

    • Search Google Scholar
    • Export Citation
  • 162.

    PriceLHNguyenMBPicozziVJKozarekRA. Portal vein thrombosis in pancreatic cancer: natural history, risk factors, and implications for patient management [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, Florida. Abstract 143.

    • Search Google Scholar
    • Export Citation
  • 163.

    AgnelliGGussoniGBianchiniC. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol2009;10:943949.

    • Search Google Scholar
    • Export Citation
  • 164.

    RiessHPelzerUOpitzB. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial [abstract]. J Clin Oncol2010;28(Suppl 15):Abstract 4033.

    • Search Google Scholar
    • Export Citation
  • 165.

    AgnelliGGeorgeDJKakkarAK. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med2012;366:601609.

    • Search Google Scholar
    • Export Citation
  • 166.

    CohenATNandiniBWillsJOOtaS. VTE prophylaxis for the medical patient: where do we stand? A focus on cancer patients. Thromb Res2010;125(Suppl 2):S2129.

    • Search Google Scholar
    • Export Citation
  • 167.

    Clarke-PearsonDLSynanISDodgeR. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol1993;168:11461153.

    • Search Google Scholar
    • Export Citation
  • 168.

    RamirezJIVassiliuPGonzalez-RuizC. Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg2003;69:941945.

    • Search Google Scholar
    • Export Citation
  • 169.

    CollaborationCTDennisMSandercockP. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet2013;382:516524.

    • Search Google Scholar
    • Export Citation
  • 170.

    AmaragiriSVLeesTA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev2000:CD001484.

  • 171.

    CohenATSkinnerJAWarwickDBrenkelI. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br2007;89:887892.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 264 263 16
PDF Downloads 55 55 2
EPUB Downloads 0 0 0